May 21, 2020 Ryvu Therapeutics to Present at Jefferies 2020 Virtual Healthcare Conference
Read More
May 18, 2020 Ryvu Therapeutics to Present Recent Data from Multiple Oncology Programs at AACR 2020 Virtual Annual Meeting II
Read More
May 14, 2020 Ryvu Therapeutics announces availability of abstracts regarding Phase 1/2 study of SEL120 and SEL24/MEN1703 accepted for presentation at 25th EHA Congress
Read More
April 16, 2020 Galapagos and Ryvu announce research collaboration
Read More
April 9, 2020 Ryvu Therapeutics Reports Annual 2019 Financial Results
Read More
March 31, 2020 Ryvu Therapeutics To Present At Solebury Trout Virtual Investor Conference
Read More
March 28, 2020 Ryvu Therapeutics receives Orphan Drug Designation from FDA for SEL120 to treat Acute Myeloid Leukemia
Read More
March 18, 2020 Successful Completion of Phase I Clinical Study of SEL24/MEN1703 in Acute Myeloid Leukemia
Read More
March 17, 2020 Ryvu Therapeutics at BIO-Europe Spring 2020
Read More
March 5, 2020 Ryvu Therapeutics to Present at the 32nd Annual ROTH Conference
Read More
February 26, 2020 Ryvu Therapeutics signs a grant agreement for the development of targeted oncology therapies based on the synthetic lethality concept
Read More
January 20, 2020 Ryvu Therapeutics scientists as co-authors of Merck poster presentation on HIF-2alpha inhibitors
Read More
January 17, 2020 Ryvu Therapeutics together with scientists from the Jagiellonian University publish a synthetic lethality research paper in Biomolecules
Read More
Posts navigation
